Sirion licenses anti-inflammatory

Article

Sirion Therapeutics has entered into an exclusive agreement with Bridge Pharma for the worldwide rights to develop and market topical ophthalmic formulations containing Bridge's proprietary anti-inflammatory agent norketotifen.

Sirion Therapeutics has entered into an exclusive agreement with Bridge Pharma for the worldwide rights to develop and market topical ophthalmic formulations containing Bridge's proprietary anti-inflammatory agent norketotifen.

Under the terms of the licensing agreement, Sirion will have the rights to manufacture, sell and distribute norketotifen for ocular use either alone or in combination with other drugs. Norketotifen is an anti-inflammatory drug with additional antihistaminic activity that may have clinical utility in various ocular conditions.

Sirion hopes to begin clinical trials with the new formulation of norketotifen in the first half of 2009.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Dr Ali Erginay discusses his EURETINA presentation
© 2024 MJH Life Sciences

All rights reserved.